MAIA Biotechnology, Inc.
corporate_fare Company Profile
MAIA Biotechnology, Inc. (NYSE:MAIA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 3 items for MAIA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 3 most recent items scored 7 or higher, the top rating is 8/10, with 1 rated 8 or above. Recent SEC coverage for MAIA spans 4, 8-K, 10-Q.
Recent high-impact activity:
- CEO Vlad Vitoc Buys 100,000 MAIA Shares for $100,000 on the Open Market
- MAIA Reports 88% Disease Control Rate in Expanded Phase 2 THIO-101 Lung Cancer Study
- MAIA Q3 Loss Narrows 19% to $7.2M; $21.3M Cash Alleviates Going-Concern Doubt
Financial Snapshot
Short Interest & Short Volume
9.02 days to coverFINRA reported short interest of 2,453,516 shares in MAIA as of the October 30, 2026 settlement, a 2.8% decrease from the prior period — about 9.0 days to cover at its recent average daily volume. On November 19, 2026, 54.7% of MAIA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.